Immunotherapy of Fungal Infections

Kausik Datta; Liise Anne Pirofski

doi:10.1016/B978-0-12-819990-9.12049-9

Immunotherapy of Fungal Infections

Kausik Datta, Liise Anne Pirofski

Medicine

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Humans regularly interact with fungi, but these interactions rarely result in disease in persons with normal immunity. In contrast, persons with immune impairment are at high risk for fungal disease. The recognition that impaired immunity is central to the pathogenesis of many fungal diseases and that antifungal agents are often ineffective in the setting of immune defects, provide a strong rationale for the development of immune-based therapies, or immunotherapy, for fungal disease. Although no such options are currently licensed, ample data demonstrate the promise of this modality. This article discusses the potential of immunotherapy for the management of fungal disease.

Original language	English (US)
Title of host publication	Encyclopedia of Mycology
Subtitle of host publication	Volume 1,2
Publisher	Elsevier
Pages	V1-468-V1-497
Volume	1
ISBN (Electronic)	9780128199909
DOIs	https://doi.org/10.1016/B978-0-12-819990-9.12049-9
State	Published - Jan 1 2021

Keywords

Antibody
Antibody-mediated immunity
Antifungal
Antigen
B-cells
Cell-mediated immunity
Cytokines
Fungal infection
Fungal vaccine
Immunomodulation
Immunotherapy
Invasive mycosis
T1
T17
T2

ASJC Scopus subject areas

General Agricultural and Biological Sciences
General Biochemistry, Genetics and Molecular Biology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/B978-0-12-819990-9.12049-9

Cite this

@inbook{aa8b8564da65448197bdbaeae4d5d730,

title = "Immunotherapy of Fungal Infections",

abstract = "Humans regularly interact with fungi, but these interactions rarely result in disease in persons with normal immunity. In contrast, persons with immune impairment are at high risk for fungal disease. The recognition that impaired immunity is central to the pathogenesis of many fungal diseases and that antifungal agents are often ineffective in the setting of immune defects, provide a strong rationale for the development of immune-based therapies, or immunotherapy, for fungal disease. Although no such options are currently licensed, ample data demonstrate the promise of this modality. This article discusses the potential of immunotherapy for the management of fungal disease.",

keywords = "Antibody, Antibody-mediated immunity, Antifungal, Antigen, B-cells, Cell-mediated immunity, Cytokines, Fungal infection, Fungal vaccine, Immunomodulation, Immunotherapy, Invasive mycosis, T1, T17, T2",

author = "Kausik Datta and Pirofski, {Liise Anne}",

year = "2021",

month = jan,

day = "1",

doi = "10.1016/B978-0-12-819990-9.12049-9",

language = "English (US)",

volume = "1",

pages = "V1--468--V1--497",

booktitle = "Encyclopedia of Mycology",

publisher = "Elsevier",

}

TY - CHAP

T1 - Immunotherapy of Fungal Infections

AU - Datta, Kausik

AU - Pirofski, Liise Anne

PY - 2021/1/1

Y1 - 2021/1/1

N2 - Humans regularly interact with fungi, but these interactions rarely result in disease in persons with normal immunity. In contrast, persons with immune impairment are at high risk for fungal disease. The recognition that impaired immunity is central to the pathogenesis of many fungal diseases and that antifungal agents are often ineffective in the setting of immune defects, provide a strong rationale for the development of immune-based therapies, or immunotherapy, for fungal disease. Although no such options are currently licensed, ample data demonstrate the promise of this modality. This article discusses the potential of immunotherapy for the management of fungal disease.

AB - Humans regularly interact with fungi, but these interactions rarely result in disease in persons with normal immunity. In contrast, persons with immune impairment are at high risk for fungal disease. The recognition that impaired immunity is central to the pathogenesis of many fungal diseases and that antifungal agents are often ineffective in the setting of immune defects, provide a strong rationale for the development of immune-based therapies, or immunotherapy, for fungal disease. Although no such options are currently licensed, ample data demonstrate the promise of this modality. This article discusses the potential of immunotherapy for the management of fungal disease.

KW - Antibody

KW - Antibody-mediated immunity

KW - Antifungal

KW - Antigen

KW - B-cells

KW - Cell-mediated immunity

KW - Cytokines

KW - Fungal infection

KW - Fungal vaccine

KW - Immunomodulation

KW - Immunotherapy

KW - Invasive mycosis

KW - T1

KW - T17

KW - T2

UR - http://www.scopus.com/inward/record.url?scp=85171514800&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85171514800&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-819990-9.12049-9

DO - 10.1016/B978-0-12-819990-9.12049-9

M3 - Chapter

AN - SCOPUS:85171514800

VL - 1

SP - V1-468-V1-497

BT - Encyclopedia of Mycology

PB - Elsevier

ER -

Immunotherapy of Fungal Infections

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this